RECOMBINANT DNA pA3, RECOMBINANT DNA pQE 30-pA3 PROVIDING PRODUCING POLYPEPTIDE A3, STRAIN E. coli M 15-A3 TRANSFORMED BY RECOMBINANT PLASMID DNA pQE 30-pA3 AND EXPRESSING RECOMBINANT POLYPEPTIDE A3, RECOMBINANT POLYPEPTIDE A3 POSSESSING ABILITY TO BIND HUMAN SERUM ALBUMIN, AND RFA TEST SYSTEM FOR QUALITATIVE DETECTION OF MICROALBUMINURIA, TEST SYSTEM FOR QUANTITATIVE DETERMINATION OF MICROALBUMINURIA Russian patent published in 2015 - IPC C07K14/315 C12N15/31 C12N15/70 C12N1/21 

FIELD: medicine, pharmaceutics.

SUBSTANCE: inventions concerns recombinant DNA pA3, recombinant plasmid DNA pQE 30-pA3, strain E.coli M 15-A3, recombinant polypeptide A3, test systems for the qualitative detection and quantitative determination of microalbuminuria. The characterised recombinant DNA pA3 is produced by a polymerase chain reaction with the use of chromosomal DNA of the strain DG 13 of group B streptococci and structured primers. An amplification fragment has been cloned by a system of expression vectors pQE-pQE 30 in E.coli M 15 to produce recombinant DNA pQE 30-pA3, which codes an amino acid sequence of the recombinant polypeptide A3 having an ability to bind human serum albumin (HSA) selectively.

EFFECT: presented inventions can be used in the medical practice and industry for producing the test systems for the detection and quantitative determination of microalbuminuria - one of the earliest signs of renal irritation in the patients suffering from diabetes mellitus and essential arterial hypertension.

6 cl, 9 dwg, 1 tbl, 8 ex